Array BioPharma and Amgen collaborate to develop autoimmune drugs

Array BioPharma and Amgen collaborate to develop autoimmune drugs

BOULDER/THOUSAND OAKS, Calif. -- California-based Amgen (NASDAQ:AMGN) and Boulder-based Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development... Read More

Wednesday July 19, 2017 0 comments Tags: Boulder, Array BioPharma, Amgen, Nicholas Saccomano, Flavius Martin

Array BioPharma submits New Drug Applications to FDA for binimetinib and encorafenib in advanced melanoma treatment

Array BioPharma submits New Drug Applications to FDA for binimetinib and encorafenib in advanced melanoma treatment

BOULDER -- Array BioPharma (Nasdaq:ARRY) today announced the submission of two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) to support use of the combination of... Read More

Wednesday July 5, 2017 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, binimetinib, encorafenib

Array BioPharma and Bristol-Myers Squibb announce strategic research collaboration

Array BioPharma and Bristol-Myers Squibb announce strategic research collaboration

BOULDER andNEW YORK CITY -- Array BioPharma (Nasdaq: ARRY) and Bristol-Myers Squibb Company (NYSE:BMY) announced the companies have entered into a clinical research collaboration to investigate... Read More

Thursday June 1, 2017 0 comments Tags: Boulder, Array BioPharma, Bristol-Myers Squibb, Ron Squarer, Fouad Namouni

Array BioPharma announces strategic collaboration with Merck

Array BioPharma announces strategic collaboration with Merck

BOULDER -- Array BioPharma Inc .(Nasdaq: ARRY) announced it has entered into a clinical trial collaboration agreement with Merck (known as MSD outsidethe United StatesandCanada) to investigate... Read More

Tuesday May 9, 2017 0 comments Tags: Boulder, Array BioPharma, Merck, Ron Squarer, binimetinib, KEYTRUDA

Array BioPharma closes on stock sale raising $132.25M

Array BioPharma closes on stock sale raising $132.25M

BOULDER -- Array BioPharma Inc . (NasdaqGM: ARRY) today announced the closing of its underwritten public offering of 21,160,000 shares of its common stock, which includes 2,760,000 shares of... Read More

Wednesday October 5, 2016 0 comments Tags: Boulder, Array BioPharma

Array BioPharma selling 18.4M shares of stock to raise $115M to fund R&D

Array BioPharma selling 18.4M shares of stock to raise $115M to fund R&D

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) today announced the pricing of an underwritten public offering of 18,400,000 shares of its common stock at a public offering price of $6.25per... Read More

Wednesday September 28, 2016 0 comments Tags: Boulder, Array BioPharma

Array BioPharma, Pierre Fabre announce positive results for cancer drug

Array BioPharma, Pierre Fabre announce positive results for cancer drug

BOULDER -- Array BioPharma (Nasdaq: ARRY) and Pierre Fabre today jointly announced top-line results from Part 1 of the Phase 3 COLUMBUS ( Co mbined L GX818 U sed with M EK162 in B RAF... Read More

Monday September 26, 2016 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, Keith T. Flaherty, encorafenib, binimetinib, Frederic Duchecesne, COLUMBUS

Array BioPharma: FDA accepts New Drug Application for melanoma

Array BioPharma: FDA accepts New Drug Application for melanoma

BOULDER -- Array BioPharma (Nasdaq: ARRY) today announced the FDA has accepted its New Drug Application (NDA) for binimetinib with a target action date under the Prescription Drug User Fee Act... Read More

Thursday September 1, 2016 0 comments Tags: Boulder, Array BioPharma, binimetinib, Dr. Victor Sandor